Drug Research

Zürich, Switzerland. Bioeq IP AG has announced that it signed a license and development agreement with Coherus BioSciences, Inc. , under which Coherus will exclusively market and distribute Bioeq’s biosimilar candidate to Lucentis in the United States (U.S.). Bioeq will...

Sygnature Discovery has added in-house high-throughput screening (HTS) to its range of drug discovery services. This is backed up by its new Leadfinder compound library. HTS allows many thousands of molecules to be tested for activity in a short period...

Becton, Dickinson and Company (BD) has launched the BD Intevia 1 mL two-step disposable autoinjector, a robust platform device combining autoinjector and pre-fillable syringe in one integrated system. BD Launches BD Intevia 1 mL two-step disposable autoinjector – a robust...

Japanese pharmaceutical firm Shionogi has signed a licence agreement with Hsiri Therapeutics for the discovery and development of therapies for non-tuberculous mycobacterial (NTM) diseases, as well as tuberculosis (TB). The agreement covers a technology that will complement the company’s previous...

GammaDelta Therapeutics, a company focussed on harnessing the unique properties of gamma delta T-cells to develop transformational immunotherapies, announced the formation of a spin-out company: Adaptate Biotherapeutics. While GammaDelta Therapeutics’ primary goal is to develop γδ T-cell based cell...

Insilico Medicine and ChemDiv, Inc. launched a new strategic collaboration to provide certain pharmaceutical and biotechnology companies with end-to-end drug discovery solutions. This collaboration combines the most advanced artificial intelligence (AI) techniques with a premium integrated drug discovery shared...

Bayer AG and its development partner Janssen Research & Development, LLC announced that the U.S. FDA has approved rivaroxaban (Xarelto) for the prevention of venous thromboembolism (VTE), or blood clots, in acutely ill medical patients at risk for thromboembolic...